Amy Schulman, a director at Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), sold a significant number of shares in the company, according to a recent SEC filing. Schulman's transactions, which took place on May 29, 2024, involved the sale of 21,700 shares at an average price of $148.57, and an additional 63 shares at $149.76, totaling over $3.2 million.
On the same day, Schulman also exercised options to acquire 30,000 shares of common stock at a price of $66.83 per share, amounting to a total transaction value of approximately $2 million. Following these transactions, Schulman's direct ownership in the company decreased to 8,436 shares of common stock.
Investors often watch the trading behavior of company insiders for insights into the company's performance and valuation. The sale of shares by Schulman was conducted under a trading plan in accordance with Rule 10b5-1, which allows company insiders to establish pre-planned transactions at a time when they are not in possession of material non-public information. Such plans provide insiders with the ability to diversify their investment portfolios and can help to avoid concerns about insider trading.
The shares were sold at prices ranging from $147.62 to $149.76, as detailed in the footnotes of the filing. These transactions were part of a structured plan adopted by Schulman on February 28, 2024, which also included provisions for covering the costs and tax obligations associated with the exercised options.
Alnylam Pharmaceuticals, headquartered in Cambridge, Massachusetts, is known for its work in the pharmaceutical industry, particularly in the development of RNA interference (RNAi) therapeutics.
The company's stock performance and insider transactions are closely monitored by investors seeking to understand market trends and the perspectives of those with in-depth knowledge of the company. The recent filing provides transparency into the trading activities of one of Alnylam's directors and offers data for investors considering their own positions in the company's stock.
InvestingPro Insights
Amid the recent insider transactions at Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY), investors may find additional context through InvestingPro metrics and tips. Notably, Alnylam's market capitalization stands at $18.78 billion, reflecting its significant presence in the pharmaceutical industry. Despite a strong revenue growth reported over the last twelve months as of Q1 2024, with an impressive increase of 75.2%, analysts are cautious, as evidenced by six of them revising their earnings downwards for the upcoming period.
Moreover, Alnylam's stock has been trading with low price volatility, and it's currently near its 52-week low, which could signal a potential entry point for investors. However, the company's P/E ratio is currently negative at -56.5, and analysts do not expect Alnylam to be profitable this year. This could be a point of consideration for investors looking at the long-term profitability of the company.
Investors considering Alnylam Pharmaceuticals as part of their portfolio should also note that the company operates with a moderate level of debt and has liquid assets that exceed short-term obligations. While Alnylam does not pay a dividend, it has shown a strong return over the last five years, a factor that might appeal to growth-focused investors.
For a deeper analysis and more InvestingPro Tips, including a total of 9 additional tips, investors can use coupon code PRONEWS24 to get an additional 10% off a yearly or biyearly Pro and Pro+ subscription at InvestingPro. These insights could provide valuable perspectives on the company's financial health and future outlook, complementing the information gleaned from insider trading activities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.